Keyphrases
Pancreatic Cancer
100%
Ixabepilone
100%
Taxanes
36%
Combination Therapy
27%
Clinical Benefit
18%
Pancreatic Adenocarcinoma
18%
Microtubule System
18%
Solid Tumors
9%
Tumor
9%
Chemotherapy
9%
Dasatinib
9%
Irinotecan
9%
Carboplatin
9%
In Cancer
9%
Patient Management
9%
Clinical Efficacy
9%
Phase II Study
9%
New Agents
9%
Biologic Therapy
9%
Monotherapy
9%
Early Phase Clinical Trials
9%
Cetuximab
9%
Epothilone B
9%
Paucity
9%
Single-arm Study
9%
Sunitinib
9%
New Combination
9%
Systemic Treatment
9%
Armamentarium
9%
Medical Oncologist
9%
Tolerable Side Effects
9%
Metastatic Pancreatic Cancer
9%
Trial Data
9%
Metastatic Pancreatic Adenocarcinoma
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Ixabepilone
100%
Taxane
36%
Combination Therapy
27%
Pancreas Adenocarcinoma
27%
Diseases
9%
Solid Malignant Neoplasm
9%
Neoplasm
9%
Side Effect
9%
Chemotherapy
9%
Dasatinib
9%
Clinical Trial
9%
Carboplatin
9%
Irinotecan
9%
Monotherapy
9%
Cetuximab
9%
Epothilone B
9%
Sunitinib
9%
Systemic Treatment
9%
Early Cancer
9%